Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ATOSSA THERAPEUTICS, INC. (ATOS)

Atossa Therapeutics releases updated corporate presentation; $26.1M cash at June 30

Neutral Impact 2 of 5 other Written later

Atossa Therapeutics made available an updated corporate presentation dated September 18, 2026, furnished under Regulation FD and not deemed filed. The presentation reports $26.1 million in cash and equivalents and no debt at June 30, 2026, and outlines timelines for its (Z)-Endoxifen oncology and rare disease programs.

Key points

  • Cash and cash equivalents of $26.1 million and no debt outstanding at June 30, 2026
  • Total operating expenses of $8.7 million in Q2 2026; June registered direct offering raised $4.0 million (net)
  • Up to $12 million additional from Series A and short-term Series B warrants, assuming full cash exercise
  • EVANGELINE Phase 2 enrollment completed; top-line data anticipated in 4Q26; IND clearance in MAS and DMD anticipated in 2H26

The filing

CompanyATOSSA THERAPEUTICS, INC. (ATOS)
Form8-K, current report
Filed with the SECSep 18, 2026, 5:00 PM ET
Accession number0001193125-26-395694

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.